Navigation Links
Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 First Quarter Results
Date:5/3/2011

G and FPG.  Lexicon expects to initiate a Phase 2b study of the tablet formulation in the second quarter of this year.
  • Lexicon commenced a Phase 1 study of LX1033, a back-up compound to LX1031 that in vitro studies indicate has the potential to be significantly more potent than LX1031.  LX1031 and LX1033 are each serotonin synthesis inhibitors that act locally in the gastrointestinal tract to reduce serotonin production by inhibiting tryptophan hydroxylase, a key enzyme in the biosynthesis of serotonin.  Lexicon anticipates completing the Phase 1 study of LX1033 in the third quarter of this year.
  • Lexicon expects to initiate a dose-ranging study in the third quarter of this year to explore higher doses of LX2931 in rheumatoid arthritis patients.  Previously reported Phase 2a results of LX2931, an inhibitor of sphingosine-1-phosphate lyase, demonstrated a favorable safety profile at all doses tested and suggested that rheumatoid arthritis patients treated with 150 mg of LX2931 once daily showed improvement in the primary efficacy endpoint of the study, the percentage of patients achieving an American College of Rheumatology 20 (ACR20) response at week 12.
  • Lexicon continued to enroll carcinoid syndrome patients in a U.S.-based Phase 2a clinical trial of LX1032, an inhibitor of tryptophan hydroxylase that reduces peripheral serotonin production without affecting brain serotonin levels, and anticipates completing enrollment in the second quarter of this year and releasing results shortly thereafter.  Lexicon also continued to enroll carcinoid syndrome patients in a second E.U.-based open-label clinical trial of LX1032.

  • Financial Results Revenues:  Lexicon's revenues for the three months ended March 31, 2011 decreased 64 percent to $0.6 million from $1.6
    '/>"/>

    SOURCE Lexicon Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Lexicon to Provide First Quarter 2011 Financial Results
    2. Lexicon Pharmaceuticals Appoints Dr. Pablo Lapuerta Chief Medical Officer
    3. Lexicon Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
    4. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Fourth Quarter and Full Year Financial Results
    5. Lexicon to Report Fourth Quarter and Year End 2010 Financial Results on February 24, 2011
    6. Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients
    7. Lexicon Pharmaceuticals to Present at the 29th Annual JPMorgan Healthcare Conference
    8. Lexicon Announces Top-Line Phase 2a Data for LX2931 in Patients with Rheumatoid Arthritis
    9. Lexicon to Provide Clinical Pipeline Update and Report Third Quarter 2010 Financial Results
    10. Lexicon Pharmaceuticals to Present at BioCentury Newsmakers in the Biotech Industry Conference Oct. 22nd
    11. Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2010 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... , Dec. 23, 2014 Echo Therapeutics, ... device company focused on skin permeation, continuous glucose ... Scott W. Hollander has been appointed Chief ... has more than 20 years of experience in ... and most recently served as Vice President, Business ...
    (Date:12/24/2014)... , December 24, 2014 ... on Global Disposable Syringe Industry of 178 ... online business intelligence library. The ... Syringe Industry is a professional and deep ...  For overview analysis, the report introduces Disposable ...
    (Date:12/24/2014)... , Dec. 23, 2014  Lockton Dunning Benefits, ... Lockton Companies, announced the addition of Vice President ... join Lockton Dunning,s Pharmacy Consulting team, Excelsior Solutions. ... relevant industry experience to the position.  Most recently, ... Sales at Diplomat Specialty Pharmacy, where she has ...
    Breaking Medicine Technology:Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 2World Disposable Syringe Market 2014 Report: China and Regional Analysis 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 4World Disposable Syringe Market 2014 Report: China and Regional Analysis 5Kim Foerster Joins Lockton Companies 2
    ... , , , ROGERS, Minn. ... conclude the new ionator EXP™ and ionator HOM™ kill the ... virus with a product that simply ionizes tap water. Slightly ... HOM™ from Activeion Cleaning Solutions, are handheld, on-demand cleaning and ...
    ... NEWTON, Mass. , Jan. 13 Microfluidics ... ( Burlington, Ontario ) to be the exclusive distributor of ... majority of Canada . ATS, which recently celebrated its ... a portfolio of synergistic products, including HORIBA particle size analyzers. ...
    Cached Medicine Technology:New ionator EXP(TM) and ionator HOM(TM) Kill Swine Flu Without Use of Chemicals 2New ionator EXP(TM) and ionator HOM(TM) Kill Swine Flu Without Use of Chemicals 3Microfluidics Enters into Exclusive Partnership with ATS Scientific to Expand Distribution in Canada 2Microfluidics Enters into Exclusive Partnership with ATS Scientific to Expand Distribution in Canada 3
    (Date:12/26/2014)... December 26, 2014 Plugin and template developers ... Volume 5 Plugin for Final Cut Pro X. , “TransPack ... light tool to pull off an industry professional look” Said ... their hands on TransPack Volume 5, a new level of ... a set of over 50 Final Cut Pro X transitions ...
    (Date:12/26/2014)... India Network Foundation, a non-profit US ... announced today a new version of “ EasySelect ”, ... right plan for their visiting parents. The technology tool ... selection process when choosing an insurance plan by showing ... a few clicks. Many elderly Asian Indian parents often ...
    (Date:12/26/2014)... December 26, 2014 DW-InductionHeating.com (DaWei Induction ... designing, researching and developing, producing and marketing of a ... the business announces their new series of induction ... of the company, induction brazing refers to ... special filler material and heat. The manager says that ...
    (Date:12/25/2014)... The microscopy market is estimated to ... $5,756.0 million by 2019. Optical microscopy is the ... microscopes product segment is expected to show the ... focus on nanotechnology, technological advancements, and increasing federal ... , Get Full Copy of Report @ ...
    (Date:12/25/2014)... December 26, 2014 The ... combines beauty, strength and durability. Today, the business ... which is valid until Jan. 30, 2015. , ... of traditional hardwood. BambooFlooringChina.com is a well-known brand ... consumers worldwide to find a reliable bamboo flooring ...
    Breaking Medicine News(10 mins):Health News:Today a new plugin was announced from Pixel Film Studios, TransPack Volume 5 for Final Cut Pro X 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 3Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2
    ... Today, during the 39th Annual Meeting of ... the Walter E. Washington Convention Center in Washington, ... Lexington) will present a poster of a study ... induce HIV-1 Reactivation." Although oral co-infections (e.g. periodontal ...
    ... ... ... ... ...
    ... with heart disease most susceptible to potential problems, small study ... could raise the risk for experiencing heartbeat irregularities among older ... suggests. , The finding stems from an assessment of a ... history of heart disease -- who were observed in an ...
    ... Food choices in years prior to illness may extend ... (HealthDay News) -- Healthy eating habits lead to longer ... In a study of 351 women with incident epithelial ... and vegetable consumption, higher vegetable consumption alone, and healthy ...
    ... ... ... , ... , , , ...
    ... ... ... ... ...
    Cached Medicine News:Health News:Periodontal pathogens enhance HIV-1 promoter activation in T cells 2Health News:MedCAREERS GROUP, Inc. Reaches Agreement in Principle to Acquire StaffMD 2Health News:MedCAREERS GROUP, Inc. Reaches Agreement in Principle to Acquire StaffMD 3Health News:MedCAREERS GROUP, Inc. Reaches Agreement in Principle to Acquire StaffMD 4Health News:MedCAREERS GROUP, Inc. Reaches Agreement in Principle to Acquire StaffMD 5Health News:Air Travel Could Raise Risk for Heartbeat Irregularities 2Health News:Air Travel Could Raise Risk for Heartbeat Irregularities 3Health News:Pre-Diagnosis Diet Linked to Ovarian Cancer Survival 2Health News:Healthcare Trust of America, Inc. Acquires an 80,562 Square Foot Medical Office Portfolio Located in Atlanta, Georgia for $19,550,000 2Health News:Healthcare Trust of America, Inc. Acquires an 80,562 Square Foot Medical Office Portfolio Located in Atlanta, Georgia for $19,550,000 3Health News:Healthcare Trust of America, Inc. Acquires an 80,562 Square Foot Medical Office Portfolio Located in Atlanta, Georgia for $19,550,000 4Health News:Healthcare Trust of America, Inc. Acquires an 80,562 Square Foot Medical Office Portfolio Located in Atlanta, Georgia for $19,550,000 5Health News:New Treatments and Good Skin Care Helping Patients Control Acne and Rosacea 2Health News:New Treatments and Good Skin Care Helping Patients Control Acne and Rosacea 3Health News:New Treatments and Good Skin Care Helping Patients Control Acne and Rosacea 4Health News:New Treatments and Good Skin Care Helping Patients Control Acne and Rosacea 5Health News:New Treatments and Good Skin Care Helping Patients Control Acne and Rosacea 6Health News:New Treatments and Good Skin Care Helping Patients Control Acne and Rosacea 7Health News:New Treatments and Good Skin Care Helping Patients Control Acne and Rosacea 8Health News:New Treatments and Good Skin Care Helping Patients Control Acne and Rosacea 9Health News:New Treatments and Good Skin Care Helping Patients Control Acne and Rosacea 10Health News:New Treatments and Good Skin Care Helping Patients Control Acne and Rosacea 11
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    Medicine Products: